<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733876</url>
  </required_header>
  <id_info>
    <org_study_id>NG-IMC001</org_study_id>
    <nct_id>NCT00733876</nct_id>
  </id_info>
  <brief_title>Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery</brief_title>
  <official_title>Phase I Clinical Trial, Dose-escalating Intra-aortic Infusion of Allogeneic , Bone Marrow-derived Multipotent Stromal Cells to Prevent and Treat Post-operative Acute Kidney Injury in Patients Who Require On-pump Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlloCure Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Mark's Hospital Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AlloCure Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine if the administration of allogeneic MSCs at defined
      doses is safe in patients who are at high risk of developing significant Acute Kidney Injury
      (AKI) after undergoing on-pump cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of MSC-specific Adverse or Serious Adverse Events</measure>
    <time_frame>In hospital, monthly x 6, yearly x 3</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Kidney Tubular Necrosis, Acute</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multipotent Stromal Cells</intervention_name>
    <description>Post-operative administration of MSC</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Administration of MSC</intervention_name>
    <description>Dose escalation protocol</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented ischemic coronary heart and/or valvular heart disease:Acceptable candidate
             for elective CABG and/or Cardiac Valve Surgery

          -  Patients at high risk for post-op AKI:Age 18 or older if at high risk for post-op AKI
             because of underlying Diabetes mellitus (type I or II), CHF, COPD Chronic Kidney
             Disease (CKD) stage 1-4

          -  Patients at high risk for post-op AKI :age &gt; 65 or combinations

          -  Patent femoral artery without aortic aneurysm

          -  Ability to give informed consent.

        Exclusion Criteria:

          -  Presence of ongoing local or systemic infection

          -  Younger than 18

          -  Participation in another clinical trial

          -  Pregnancy

          -  Contraindication to general anesthesia

          -  Prisoner

          -  Dialysis patient (CKD-6) or patient with CKD-5

          -  History of malignancy except non-melanoma skin cancer

          -  Occluded Groin arteries

          -  Uncontrolled Diabetes mellitus (HbA1c &gt; 10, history of diabetic ketoacidosis or
             osmolar coma within the last three months)

          -  Non-healing foot ulcers.

          -  Clinical evidence of severe peripheral vascular disease (ABI &lt; 0.3)

          -  Coronary Angiogram &lt; 7 days before surgery

          -  Inadequate pre-operative time to obtain baseline kidney function data due to
             urgent/emergent surgery

          -  Unstable myocardium (evolving myocardial infarction), cardiogenic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christof Westenfelder, MD</last_name>
    <role>Study Director</role>
    <affiliation>AlloCure Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mark's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Renal Failure Cardiac Surgery Stem Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Kidney Tubular Necrosis, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

